Skip to main content
Premium Trial:

Request an Annual Quote

Genmab Extends License for IDBS' ActivityBase Screening Software

NEW YORK (GenomeWeb News) — Dutch company Genmab has extended its agreement to use ID Business Solutions’ ActivityBase Xtended Edition screening software, Guildford, UK-based IDBS said today.
 
Under the agreement, Genmab’s Hybridoma Discovery department will use the software to mange the design, capture, storage, and retrieval of plate-based screening data, IDBS said.
 
IDBS said Genmab initially licensed the software in 2006 to manage data from functional screening of human monoclonal antibody therapies, and now has “more than doubled” that number of ActivityBase XE licenses.
 
IDBS’ founder and CEO Neil Kipling said the software supports high-throughput and high-content screening and “new screening methodologies.”
 
Financial terms of the agreement were not released.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.